Intuitive Surgical commands roughly 80% of the global surgical robotics market through its flagship da Vinci platform, with an installed base exceeding 7,000 systems worldwide. Since its founding in 1995 and headquarters’ move to Sunnyvale, CA, the company has expanded its procedure portfolio across urology, gynecology, cardiothoracic, head and neck, and general surgery. Hospitals face significant switching costs once the da Vinci system is in place, reinforcing Intuitive’s position as the industry standard and driving strong customer retention rates above 90%.

Intuitive Surgical’s business model combines upfront robotics sales with a high-margin consumables and service segment, generating more than 65% of revenues from instrument and accessory sales. Procedure volumes have grown at a double-digit annual rate over the past three years, fuelling a recurring-revenue stream that now represents the majority of quarterly income. Despite a forward P/E near 64, the company maintains a pristine balance sheet, with cash and short-term investments reportedly exceeding $3 billion and no material long-term debt maturities until 2027.

The company’s ongoing R&D investment, averaging over 12% of annual revenues, has yielded a steady cadence of platform enhancements and next-generation instruments. Clinical studies continue to highlight superior patient outcomes—such as reduced hospital stays by up to 30% in select procedures—which bolster hospital ROI calculations. With recent approvals for single-port robotics and early trials in neurosurgical applications, Intuitive is positioning itself for further penetration into under-served specialties, supporting management’s long-term revenue growth target of 15%–20% annually.